BR0314369A - Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado - Google Patents

Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado

Info

Publication number
BR0314369A
BR0314369A BR0314369-4A BR0314369A BR0314369A BR 0314369 A BR0314369 A BR 0314369A BR 0314369 A BR0314369 A BR 0314369A BR 0314369 A BR0314369 A BR 0314369A
Authority
BR
Brazil
Prior art keywords
cell
agent
growth
cancer
methods
Prior art date
Application number
BR0314369-4A
Other languages
English (en)
Inventor
Sally-Anne Stephenson
Original Assignee
Queen Elizabeth Hospital Res F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Elizabeth Hospital Res F filed Critical Queen Elizabeth Hospital Res F
Publication of BR0314369A publication Critical patent/BR0314369A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODOS PARA INIBIR O CRESCIMENTO CANCEROSO DE UMA CéLULA, PARA INDUZIR MORTE CELULAR DE UMA CéLULA DE CâNCER, PARA TRATAR OU PREVENIR CâNCER EM UM INDIVìDUO E PARA IDENTIFICAR UM AGENTE QUE INIBE O CRESCIMENTO CANCEROSO DE UMA CéLULA, AGENTE, E, ANTICORPO EPHB4 PURIFICADO". A presente invenção provê métodos para inibir o crescimento canceroso de uma célula usando um anticorpo ou uma porção de ligação a antígeno do mesmo que se liga a um epítopo do polipeptídeo EphB4. Também são providos anticorpos purificados de EphB4 A invenção também provê métodos para prevenir ou tratar câncer. A invenção também refere-se a métodos de identificar agentes que podem inibir o crescimento canceroso de uma célula.
BR0314369-4A 2002-09-16 2003-09-16 Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado BR0314369A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002951409A AU2002951409A0 (en) 2002-09-16 2002-09-16 Methods for regulating cancer
PCT/AU2003/001209 WO2004024773A1 (en) 2002-09-16 2003-09-16 Methods for regulating cancer

Publications (1)

Publication Number Publication Date
BR0314369A true BR0314369A (pt) 2005-08-09

Family

ID=27792678

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314369-4A BR0314369A (pt) 2002-09-16 2003-09-16 Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado

Country Status (15)

Country Link
US (1) US7722866B2 (pt)
EP (1) EP1546205B1 (pt)
JP (1) JP4799863B2 (pt)
KR (1) KR20050072744A (pt)
CN (1) CN1694902B (pt)
AT (1) ATE486892T1 (pt)
AU (1) AU2002951409A0 (pt)
BR (1) BR0314369A (pt)
CA (1) CA2499130A1 (pt)
DE (1) DE60334820D1 (pt)
ES (1) ES2355503T3 (pt)
MX (1) MXPA05002894A (pt)
NZ (1) NZ539203A (pt)
WO (1) WO2004024773A1 (pt)
ZA (1) ZA200502863B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP4762889B2 (ja) 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
NZ549787A (en) * 2004-03-12 2010-05-28 Vasgene Therapeutics Inc Antibodies binding to EphB4 for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP1799867A2 (en) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
AU2013200383B2 (en) * 2006-01-05 2016-05-12 Genentech,Inc. Anti-EphB4 antibodies and methods using same
AU2007248444B2 (en) * 2006-01-05 2012-10-25 Genentech, Inc. Anti-EphB4 antibodies and methods using same
CN101395183B (zh) * 2006-01-05 2013-08-07 健泰科生物技术公司 抗ephb4抗体及其使用方法
TWI391402B (zh) * 2006-01-05 2013-04-01 Genentech Inc 抗ｅｐｈｂ４抗體及使用該抗體之方法
WO2008025099A1 (en) 2006-08-31 2008-03-06 A.C.N. 135 493 391 Pty Ltd As Trustee For Conca Unit Trust Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions
WO2008104803A2 (en) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2137216A2 (en) * 2007-03-12 2009-12-30 Vasgene Therapeutics, Inc. Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
US20110009323A1 (en) * 2007-06-15 2011-01-13 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
WO2009023185A1 (en) 2007-08-13 2009-02-19 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
AU2015204311B2 (en) * 2007-11-29 2017-06-08 Molecular Health Gmbh Novel tissue protective erythropoietin receptor (NEPOR) and methods of use
HUE026591T2 (hu) * 2007-11-29 2016-06-28 Molecular Health Gmbh Szövetvédõ eritropoietin receptor (nepor) és alkalmazási eljárásai

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
JP2002530350A (ja) * 1998-11-20 2002-09-17 ジェネンテック・インコーポレーテッド 血管障害を処置するためのＥｐｈレセプターのアンタゴニストおよびアゴニストについての使用
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2002212292A1 (en) * 2000-09-29 2002-04-08 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
KR100576674B1 (ko) 2001-06-20 2006-05-10 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
JP4762889B2 (ja) * 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物

Also Published As

Publication number Publication date
DE60334820D1 (de) 2010-12-16
NZ539203A (en) 2008-05-30
ZA200502863B (en) 2006-06-28
KR20050072744A (ko) 2005-07-12
US20060134118A1 (en) 2006-06-22
WO2004024773A1 (en) 2004-03-25
AU2002951409A0 (en) 2002-09-26
JP4799863B2 (ja) 2011-10-26
ES2355503T3 (es) 2011-03-28
US7722866B2 (en) 2010-05-25
CN1694902A (zh) 2005-11-09
EP1546205A4 (en) 2006-05-03
EP1546205B1 (en) 2010-11-03
EP1546205A1 (en) 2005-06-29
JP2006517906A (ja) 2006-08-03
CN1694902B (zh) 2012-10-10
MXPA05002894A (es) 2005-10-05
CA2499130A1 (en) 2004-03-25
ATE486892T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
BR0312692A (pt) anticorpos selecionados e peptìdeos de duramicina que se ligam a fosfolipìdios aniÈnicos e aminofosfolipìdios e seus usos no tratamento de infecções virais e cáncer
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
ATE530577T1 (de) Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
BRPI0409879A (pt) composições e métodos para imunoterapia especìfica wt1
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DK1654287T3 (da) CD20-bindende polypeptidsammensætninger
BR0207977A (pt) Métodos de combinação de inibição de crescimento tumoral com um antagonista de receptor de fator de crescimento endotelial
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
BR0114978A (pt) Composições e métodos que são úteis no tratamento de condições ou doenças inflamatórias, metabólicas, e proliferativas celulares
MX2009001440A (es) Composiciones y metodos que utilizan anticuerpos anti-cs1 para tratar mieloma multiple.
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
WO2005090406A3 (en) Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
BRPI0414513A (pt) kid3 e anticorpos de kid3 que se ligam a ele
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
EA202192587A1 (ru) Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей
ATE312622T1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2323 DE 14-07-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI